This inventor holds 1 USPTO granted patent and 1 published patent application. Top assignees: Dainippon Sumitomo Pharma Co., Ltd., Other. Active years: 2010.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
1 out of 140 
1 out of 834,659 Years Active: 2010
Title: Yuki Nabeta: Innovator in Tumor Antigen Research
Introduction
Yuki Nabeta is a prominent inventor based in Sapporo, Japan. She has made significant contributions to the field of cancer research, particularly in the development of tumor antigen proteins. Her innovative work has the potential to advance therapeutic strategies for cancer treatment.
Latest Patents
Yuki Nabeta holds a patent for a tumor antigen protein and its use as an inducer of cytotoxic T cells. The patent describes a protein that comprises the same or substantially the same amino acid sequence as that shown in SEQ ID NO: 2, or a peptide derived from this protein. This invention is crucial for enhancing immune responses against tumors.
Career Highlights
Throughout her career, Yuki has worked with Dainippon Sumitomo Pharma Co., Ltd., where she has contributed to various research projects. Her expertise in protein engineering and immunology has positioned her as a valuable asset in the pharmaceutical industry.
Collaborations
Yuki has collaborated with notable colleagues, including Noriyuki Sato and Tomohide Tsukahara. These partnerships have fostered a collaborative environment that encourages innovation and the sharing of ideas.
Conclusion
Yuki Nabeta's work in tumor antigen research exemplifies the impact of innovative thinking in the medical field. Her contributions are paving the way for new cancer therapies that could improve patient outcomes.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile